This article has been cited by
1Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms
Koulenti, Xu, Mok, Song, Karageorgopoulos, Armaganidis, Lipman, SotiriosTsiodras
Microorganisms.2019;7(8)270
[DOI]
2Prevention and Treatment of Multidrug-Resistant Organisms in End-Stage Renal Disease
John K. Midturi,Sangeetha Ranganath
Advances in Chronic Kidney Disease.2019;26(1)51
[DOI]
3Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion
Urania Rappo,Michael W. Dunne,Sailaja Puttagunta,James S. Baldassarre,Shengfang Su,Daksha Desai-Krieger,Megumi Inoue
Antimicrobial Agents and Chemotherapy.2019;63(11)51
[DOI]
4Emerging antibacterial and antiviral drugs for treating respiratory tract infections
Marco Mantero,Paola Rogliani,Mario Cazzola,Francesco Blasi,Marta Di Pasquale
Expert Opinion on Emerging Drugs.2018;23(3)185
[DOI]
5Mammary Dysbiosis and Nipple Blebs Treated With Intravenous Daptomycin and Dalbavancin
Katrina B. Mitchell,Anne Eglash,Ethan T. Bamberger
Journal of Human Lactation.2019;23(3)089033441986221
[DOI]
6Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections
Jacqueline T. Bork,Emily L. Heil,Shanna Berry,Eurides Lopes,Rohini Davé,Bruce L. Gilliam,Anthony Amoroso
Infectious Diseases and Therapy.2019;8(2)171
[DOI]
  Feedback 
  Subscribe